Valuation: Ovid Therapeutics Inc.

Market Cap 43Cr 37Cr 34Cr 32Cr 60Cr 4.08TCr 61Cr 408.14Cr 159.8Cr 2.03TCr 160.5Cr 156.99Cr 6.82TCr P/E 2026 *
-4.74x
P/E 2027 * -4.29x
Enterprise Value 43Cr 37Cr 34Cr 32Cr 60Cr 4.08TCr 61Cr 408.14Cr 159.8Cr 2.03TCr 160.5Cr 156.99Cr 6.82TCr EV / Sales 2026 *
3,976x
EV / Sales 2027 * 2,564x
Free-Float
92.96%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+1.97%
1 week-2.71%
Current month-13.20%
1 month-13.20%
3 months-15.70%
6 months+49.68%
Current year+43.25%
1 week 2.24
Extreme 2.24
2.48
1 month 2.24
Extreme 2.24
2.82
Current year 1.36
Extreme 1.36
3.1
1 year 0.48
Extreme 0.475
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.2
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Free

Chief Financial Officer

50,000 0.0268%
06/07/26 Other

Chief Financial Officer

4,50,625 0.2414%
07/04/26 Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+2.40%-2.71%+367.00%-34.96% 43Cr
-3.74%-6.32%+42.70%+63.37% 5.52TCr
-0.81%-0.33%+27.15%+81.12% 5.56TCr
+0.14%+0.84%-15.64%-14.73% 2.35TCr
-1.62%-5.52%-3.52%+359.39% 2.24TCr
-4.01%-2.68%+12.50%-12.70% 2.06TCr
-1.23%-3.15%+26.00%-33.84% 1.74TCr
-3.34%-6.96%+22.02%+515.48% 1.52TCr
+0.93%+0.20%+51.30%+182.90% 1.39TCr
-5.09%-13.14%+151.85%+272.20% 1.37TCr
Average -1.70%-1.77%+68.13%+137.82% 2.38TCr
Weighted average by Cap. -2.10%-0.47%+31.19%+121.57%

Financials

2026 *2027 *
Net sales 1L 93.37T 86.71T 79.97T 2L 1.03Cr 2L 10.27L 4L 50.97L 4L 4L 1.71Cr 2L 1L 1L 1L 2L 1.59Cr 2L 15.92L 6L 79.03L 6L 6L 2.66Cr
Net income -7.71Cr -6.7Cr -6.22Cr -5.74Cr -11Cr -736.27Cr -11Cr -74Cr -29Cr -365.67Cr -29Cr -28Cr -1.23TCr -8.98Cr -7.8Cr -7.25Cr -6.68Cr -13Cr -857.69Cr -13Cr -86Cr -34Cr -425.98Cr -34Cr -33Cr -1.43TCr
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
31/26/31 $2.335 +1.97% 7,64,380
29/26/29 $2.290 -2.97% 6,48,338
28/26/28 $2.360 +0.43% 13,51,124
27/26/27 $2.350 +0.86% 10,48,327
24/26/24 $2.330 -2.92% 9,84,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.290USD
Average target price
5.471USD
Spread / Average Target
+138.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock